In March 2014, the progress of the pre-clinical study on the Unravelling Stent was covered by Norwegian national TV, NRK.
On the 10th of March 2014, the ErneyGraft was granted a US patent by USPTO. It also passed the time limit for oppositions in the EU through EPO, and no complaints have been filed.
In December 2013, animal studies was initiated in sheep at St Olav’s Hospital to investigate if the Unravelling Stent causes less restenosis compared to traditional stents if implanted in the iliac artery. Male sheep has been used for this study.
From January 2014, project manager Emma Wejedal is recruited to the GraftCraft management. Emma has her background in bioengineering and entrepreneurship, with start-up experience from Monivent.